In patients with POMC or LEPR deficiency, most evaluable patients showed HRQOL impairment at baseline but experienced clinically meaningful improvement after 52 weeks of setmelanotide treatment [125]. The gene discussed is LEPR; the disease is hyperinsulinemic hypoglycemia, familial, 4.